A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2- breast cancer patients using and FDA TR-PCR cleared test3
An Integrated Multiplexing Approach Identifies IDO1 as a Biomarker for Recurrence of Rare Ovarian Granulosa Cell Tumors
An Integrated Multiplexing Approach for the Immunoprofiling of the Tumor Microenvironment of Ovarian Granulosa Cell Tumors
The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression
EBV–Associated Lymphoproliferative Disorders: Update in Classification
Using a Multiplexed Immunofluorescence Approach to Compare Immune Cell Populations in Subtypes on Non-Small Cell Lung Cancer
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx
Predictive Markers Require Thorough Analytic Validation